Valuation: Kodiak Sciences Inc.

Market Cap 6.22B 5.57B 5.12B 4.64B 8.68B 591B 8.84B 61.11B 24.53B 311B 23.35B 22.85B 980B P/E 2026 *
-24.3x
P/E 2027 * -25.8x
Enterprise Value 5.9B 5.28B 4.86B 4.4B 8.23B 560B 8.38B 57.93B 23.26B 295B 22.13B 21.66B 929B EV / Sales 2026 *
-
EV / Sales 2027 * 122x
Free-Float
94.84%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Kodiak Sciences Inc.

1 day-1.22%
1 week+13.18%
Current month+4.62%
1 month+4.62%
3 months+133.36%
6 months+128.10%
Current year+254.72%
1 week 87.61
Extreme 87.6075
103.73
1 month 79.06
Extreme 79.06
103.73
Current year 20.88
Extreme 20.88
104
1 year 15.83
Extreme 15.8334
104
3 years 1.43
Extreme 1.43
104
5 years 1.37
Extreme 1.37
131.97
10 years 1.37
Extreme 1.37
171.21
Manager TitleAgeSince
Chief Executive Officer 53 2008-12-31
Director of Finance/CFO 64 2015-12-31
Chief Tech/Sci/R&D Officer - 2023-12-31
Director TitleAgeSince
Chairman 53 2008-12-31
Director/Board Member 57 2015-08-31
Director/Board Member 55 2018-07-17
Date Insider Type Main position Quantity % Market Cap. Importance
9/29/26
Baker Bros. Advisors LP
BuyCompany 33,726 0.0537%
9/28/26
Baker Bros. Advisors LP
BuyCompany 418,323 0.6656%
9/28/26
Baker Bros. Advisors LP
BuyCompany 807,840 1.2854%
Change 5-day change 1-year change 3-year change Capi.($)
-1.22%+13.18%+371.16%+6,884.51% 6.22B
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.18%+8.10%+80.19%+874.14% 40.06B
Weighted average by Cap. +0.16%+5.56%+53.51%+290.16%

Financials

2026 *2027 *
Net sales - 49.14M 44.01M 40.48M 36.68M 68.56M 4.67B 69.85M 483M 194M 2.45B 184M 180M 7.74B
Net income -266M -238M -219M -198M -371M -25.21B -377M -2.61B -1.05B -13.26B -997M -975M -41.83B -272M -243M -224M -203M -379M -25.78B -386M -2.67B -1.07B -13.56B -1.02B -997M -42.77B
Net Debt -324M -290M -267M -242M -452M -30.73B -460M -3.18B -1.28B -16.16B -1.21B -1.19B -50.97B -212M -190M -175M -158M -296M -20.12B -301M -2.08B -836M -10.58B -795M -778M -33.38B
Projected Income Statement - Annual - Kodiak Sciences Inc.
Logo Kodiak Sciences Inc.
Kodiak Sciences Inc. is a precommercial retina-focused biotechnology company. The Company is developing a portfolio of three late-stage clinical programs. Zenkuda (tarcocimab tedromer) has a BLA-ready profile in diabetic retinopathy, retinal vein occlusion and wet AMD, and, together with KSI-501, is being explored in the BLA-facing Phase 3 DAYBREAK wet AMD study. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI). Its Antibody Biopolymer Conjugate (ABC) Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its second investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high prevalence retinal vascular diseases to address the leading unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy.
Employees
141
Date Price Change Volume
26-10-30 US$99.18 -1.22% 568,099
26-10-29 US$100.40 +3.46% 1,174,178
26-10-28 US$97.04 +6.26% 976,438
26-10-27 US$91.32 +1.92% 1,010,420
26-10-26 US$89.60 +2.25% 927,029
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Kodiak Sciences Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
99.18USD
Average target price
121.67USD
Spread / Average Target
+22.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Kodiak Sciences Inc.